KRAS and cancer: The first KRASG12D-selective inhibitor, MRTX1133, demonstrated near 1,000-fold selectivity for inhibiting KRASG12D signaling and KRASG12D-mutant cancer cell growth as compared with KRAS WT (130, 131).